In a report released today, Andrew D’silva from B.Riley FBR maintained a Buy rating on OptimizeRx Corporation (OPRX), with a price target of $21.75. The company’s shares closed yesterday at $10.81.
D’silva observed:
“Buy-rated OptimizeRx Corporation (OPRX) reports 1Q19 results AMC on Wednesday, 5/8, and will hold a conference call at 4:30pm ET the same day. The dial-in and conference ID numbers are and 3593483, respectively. We are comfortable with our estimates from our last earnings update note and believe our estimates are beatable, as we are modeling a greater seasonal impact to 1Q sales than has historically been seen, which should more than offset headwinds experienced from the government shutdown this January. Furthermore, this will be OPRX’s first full quarter with CareSpeak as the acquisition was completed during 4Q18. We believe consensus estimates, which approximate ours, are reasonable/beatable as well.”
According to TipRanks.com, D’silva is a 4-star analyst with an average return of 7.4% and a 37.7% success rate. D’silva covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Sensus Healthcare Inc, and Anixa Biosciences Inc.
OptimizeRx Corporation has an analyst consensus of Moderate Buy, with a price target consensus of $21.75.
See today’s analyst top recommended stocks >>
Based on OptimizeRx Corporation’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $109.9K. In comparison, last year the company had a GAAP net loss of $189.2K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is neutral on the stock. Earlier this month, Douglas Baker, the CFO of OPRX bought 5,000 shares for a total of $15,750.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OptimizeRx Corp. engages in the provision of digital health messaging via electronic health records, which serves as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers EHR workflow solutions which include financial messaging, patient education, and brand messaging; and brand support.
